drugset
drugset / Trial / NCT00996892

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00996892 ↗

Phase 1 Terminated 178 enrolled Genentech, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.

Timeline

Start
2009-11
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobimetinib Small molecule 20 mg Oral
Subject Cobimetinib Small molecule 40 mg Oral
Subject Cobimetinib Small molecule 100 mg Oral
Subject Pictilisib Small molecule 80 mg Oral
Subject Pictilisib Small molecule 130 mg Oral

Indications

cancer